Plant-derived phytochemicals have been interested in as nutraceuticals for preventing the onset and progress of diabetes mellitus and its serious complications in recent years. Moringa oleifera Lam. is used in vegetables and in herbal medicine for its health-promoting properties against various diseases including diabetes mellitus. This study aimed to examine an effect of Moringa oleifera on diabetic hyperglycemia and dyslipidemia by meta-analyzing the current evidence of diabetic rodent models. Peer-reviewed studies written in English from two databases, PubMed and Embase, were searched to 30 April 2021. Studies reporting blood glucose or lipid levels in diabetic rodents with and without receiving extracts of Moringa oleifera were included. Forty-four studies enrolling 349 diabetic rodents treated with extracts of Moringa oleifera and 350 diabetic controls reported blood glucose levels. The pooled effect size was −3.92 (95% CI: −4.65 to −3.19) with a substantial heterogeneity. This effect was likely to be, at least in part, modified by the type of diabetic models. Moreover, diabetic hypertriglyceridemia and hypercholesterolemia were also significantly improved in diabetic rodent models treated with Moringa oleifera.

Research on nutraceuticals has focused on reducing the onset, progression, and significant consequences of diabetes mellitus. Arctium lappa Lam. is a great source of plant fibers and polyphenols that have anti-disease benefits, including those for diabetes mellitus. This study sought to determine the impact of Arctium lappa Lam. extracts and its associated lignans on diabetic hyperglycemia and dyslipidemia by conducting meta-analyses of the available research using diabetic rodents. English-language peer-reviewed articles were searched by PubMed and Embase up until 10 August 2022. Included were studies comparing the blood glucose and/or lipid levels of diabetic rodents given either extracts of Arctium lappa Lam. and its related lignans or vehicles. Blood glucose levels were reported in 16 studies involving 168 diabetic mice or rats treated with Arctium lappa Lam. and 168 diabetic controls. The pooled effect size was −1.42 [95% CI: −1.84 to −1.00] with significant heterogeneity. Type of diabetic model was found to be the prominent covariate that explained, at least partially, the heterogeneity. Moreover, diabetic rodents treated with Arctium lappa Lam. showed a notable improvement in their hypertriglyceridemia and hypercholesterolemia.